How much profit has Amgen made this year?
Amgen has made 11.63 B USD this year.
Amgen Net Income 2025
Amgen Net Income
11.63 B USD
Ticker
AMGN
ISIN
US0311621009
WKN
867900
In 2025, Amgen's profit amounted to 11.63 B USD, a 184.32% increase from the 4.09 B USD profit recorded in the previous year.
The Amgen Net Income history
| YEAR | NET INCOME (B USD) |
|---|---|
| 2030e | 14 |
| 2029e | 13.13 |
| 2028e | 12.61 |
| 2027e | 12.37 |
| 2026e | 11.92 |
| 2025e | 11.63 |
| 2024 | 4.09 |
| 2023 | 6.72 |
| 2022 | 6.55 |
| 2021 | 5.89 |
| 2020 | 7.26 |
| 2019 | 7.84 |
| 2018 | 8.39 |
| 2017 | 1.98 |
| 2016 | 7.72 |
| 2015 | 6.94 |
| 2014 | 5.16 |
| 2013 | 5.08 |
| 2012 | 4.35 |
| 2011 | 3.68 |
| 2010 | 4.63 |
| 2009 | 4.61 |
| 2008 | 4.05 |
| 2007 | 3.08 |
| 2006 | 2.95 |
| 2005 | 3.67 |
Amgen Revenue, EBIT, Net Income
3 years
5 years
10 years
25 Years
Max
Loading chart...
Revenue
EBIT
Net Income
Details
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Amgen, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Amgen from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Amgen’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Amgen. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Amgen’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Amgen’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Amgen’s growth potential.
Amgen Revenue, EBIT and net profit per share
| Date | Amgen Revenue | Amgen EBIT | Amgen Net Income |
|---|---|---|---|
| 2030e | 41.09 B undefined | 0 undefined | 14 B undefined |
| 2029e | 39.48 B undefined | 17.42 B undefined | 13.13 B undefined |
| 2028e | 38.27 B undefined | 16.84 B undefined | 12.61 B undefined |
| 2027e | 37.99 B undefined | 16.38 B undefined | 12.37 B undefined |
| 2026e | 37.03 B undefined | 16.18 B undefined | 11.92 B undefined |
| 2025e | 36.41 B undefined | 16.02 B undefined | 11.63 B undefined |
| 2024 | 33.42 B undefined | 9.66 B undefined | 4.09 B undefined |
| 2023 | 28.19 B undefined | 8.16 B undefined | 6.72 B undefined |
| 2022 | 26.32 B undefined | 10.13 B undefined | 6.55 B undefined |
| 2021 | 25.98 B undefined | 9.14 B undefined | 5.89 B undefined |
| 2020 | 25.42 B undefined | 9.14 B undefined | 7.26 B undefined |
| 2019 | 23.36 B undefined | 9.72 B undefined | 7.84 B undefined |
| 2018 | 23.75 B undefined | 10.64 B undefined | 8.39 B undefined |
| 2017 | 22.85 B undefined | 10.34 B undefined | 1.98 B undefined |
| 2016 | 22.99 B undefined | 9.79 B undefined | 7.72 B undefined |
| 2015 | 21.66 B undefined | 8.53 B undefined | 6.94 B undefined |
| 2014 | 20.06 B undefined | 6.57 B undefined | 5.16 B undefined |
| 2013 | 18.68 B undefined | 6.17 B undefined | 5.08 B undefined |
| 2012 | 17.27 B undefined | 5.82 B undefined | 4.35 B undefined |
| 2011 | 15.58 B undefined | 5.2 B undefined | 3.68 B undefined |
| 2010 | 15.05 B undefined | 6.97 B undefined | 4.63 B undefined |
| 2009 | 14.64 B undefined | 6.81 B undefined | 4.61 B undefined |
| 2008 | 15 B undefined | 5.52 B undefined | 4.05 B undefined |
| 2007 | 14.77 B undefined | 5.25 B undefined | 3.08 B undefined |
| 2006 | 14.27 B undefined | 5.01 B undefined | 2.95 B undefined |
| 2005 | 12.43 B undefined | 4.84 B undefined | 3.67 B undefined |
Amgen stock margins
The Amgen margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Amgen. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Amgen.
3 years
5 years
10 years
25 Years
Max
Loading chart...
Gross margin
EBIT margin
Profit margin
Details
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Amgen's sales revenue. A higher gross margin percentage indicates that the Amgen retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Amgen's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Amgen's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Amgen's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Amgen. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Amgen's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Amgen Margin History
| Amgen Gross margin | Amgen Profit margin | Amgen EBIT margin | Amgen Profit margin |
|---|---|---|---|
| 2030e | 68.71 % | 0 % | 34.08 % |
| 2029e | 68.71 % | 44.13 % | 33.25 % |
| 2028e | 68.71 % | 43.99 % | 32.94 % |
| 2027e | 68.71 % | 43.11 % | 32.55 % |
| 2026e | 68.71 % | 43.69 % | 32.2 % |
| 2025e | 68.71 % | 43.99 % | 31.94 % |
| 2024 | 68.71 % | 28.9 % | 12.24 % |
| 2023 | 70.15 % | 28.96 % | 23.83 % |
| 2022 | 75.66 % | 38.49 % | 24.89 % |
| 2021 | 75.16 % | 35.2 % | 22.68 % |
| 2020 | 75.77 % | 35.95 % | 28.57 % |
| 2019 | 81.35 % | 41.61 % | 33.57 % |
| 2018 | 82.73 % | 44.78 % | 35.35 % |
| 2017 | 82.19 % | 45.25 % | 8.66 % |
| 2016 | 81.9 % | 42.57 % | 33.59 % |
| 2015 | 80.49 % | 39.38 % | 32.03 % |
| 2014 | 77.96 % | 32.74 % | 25.71 % |
| 2013 | 82.08 % | 33.01 % | 27.21 % |
| 2012 | 81.47 % | 33.69 % | 25.17 % |
| 2011 | 82.62 % | 33.38 % | 23.64 % |
| 2010 | 85.25 % | 46.28 % | 30.74 % |
| 2009 | 85.72 % | 46.48 % | 31.45 % |
| 2008 | 84.7 % | 36.81 % | 27.01 % |
| 2007 | 82.75 % | 35.52 % | 20.84 % |
| 2006 | 85.32 % | 35.11 % | 20.68 % |
| 2005 | 83.25 % | 38.93 % | 29.56 % |
Amgen Aktienanalyse
What does Amgen do?
Amgen Inc. is a global biotechnology company focused on the development and production of pharmaceuticals. It was founded in 1980 by William K. Bowes Jr. and George B. Rathmann in Thousand Oaks, California/USA. The founders had the vision to create new treatment options for serious diseases such as cancer, autoimmune diseases, and osteoporosis. Amgen faced difficulties in its early days due to limited financial resources and setbacks in research. However, the company succeeded in developing the first recombinant therapeutic protein drug, Erythropoietin (EPO), and bringing it to the market. Today, Amgen has become one of the largest biotechnology companies in the world with over 24,000 employees worldwide. The company is known for its research and development work in oncology, kidney diseases, blood disorders, inflammation, and bone diseases. Amgen's business model involves investing in research and development to develop new drugs and commercialize them in global markets. The company follows a "biological platform" strategy, focusing on biotechnology products based on proteins and antibodies. Amgen has several product lines, including Biologics, Biosimilars, and Small Molecules. Biologics are protein-based drugs manufactured using living cells. Biosimilars are products that have similar structures to existing biologics. Small Molecules are chemically manufactured drugs. Some of Amgen's most well-known products include Epogen and Aranesp (both Erythropoietin-releasing hormones), Neulasta and Neupogen (both granulocyte colony-stimulating factors), Enbrel (a TNF inhibitor for the treatment of rheumatoid arthritis), Prolia and Xgeva (both Denosumab inhibitors for the treatment of osteoporosis), and Blincyto (a bispecific antibody against cancer). Amgen is also involved in cancer immunotherapy and has a range of medications in its portfolio, including a CAR-T immunotherapy used for certain forms of acute lymphoblastic leukemia (ALL). In addition, Amgen specializes in the development of biosimilars. In 2017, the company introduced six biosimilars to the market, including copies of Enbrel and Humira for the treatment of rheumatoid arthritis. Biosimilars have the potential to reduce the costs of patient treatment as they are typically cheaper than the original products. Furthermore, Amgen works closely with other companies and research institutions to develop innovative products and technologies. The company has numerous partnerships and licensing agreements with other companies in the biotech industry to accelerate its growth and expand its product pipeline. Overall, Amgen has successfully established itself as one of the leading biotechnology companies in the world. It is known for its innovative products, investments in research and development, and partnerships with other companies. With its wide product portfolio and commitment to producing high-quality biological products, Amgen will continue to play an important role in the healthcare industry. Amgen ist eines der beliebtesten Unternehmen auf Eulerpool.com.Amgen revenue by segment
95 % Human Therapeutics
5 % Other
Net Income Details
Understanding Amgen's Profit Margins
The profit margins of Amgen represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Amgen's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating Amgen's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
Amgen's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When Amgen’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about Amgen stock
How has the profit developed compared to last year?
The profit has increased by 184.32% compared to last year increased
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does Amgen publish its earnings?
Amgen publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of Amgen?
The profits of Amgen are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of Amgen?
You can learn more about the earnings of Amgen by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does Amgen pay?
Over the past 12 months, Amgen paid a dividend of 9.13 USD . This corresponds to a dividend yield of about 3.08 %. For the coming 12 months, Amgen is expected to pay a dividend of 13.93 USD.
What is the dividend yield of Amgen?
The current dividend yield of Amgen is 3.08 %.
When does Amgen pay dividends?
Amgen pays a quarterly dividend. This is distributed in the months of December, March, June, September.
How secure is the dividend of Amgen?
Amgen paid dividends every year for the past 20 years.
What is the dividend of Amgen?
For the upcoming 12 months, dividends amounting to 13.93 USD are expected. This corresponds to a dividend yield of 4.71 %.
In which sector is Amgen located?
Amgen is assigned to the 'Health' sector.
Wann musste ich die Aktien von Amgen kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Amgen from 9/12/2025 amounting to 2.38 USD, you needed to have the stock in your portfolio before the ex-date on 8/22/2025.
When did Amgen pay the last dividend?
The last dividend was paid out on 9/12/2025.
What was the dividend of Amgen in the year 2024?
In the year 2024, Amgen distributed 8.64 USD as dividends.
In which currency does Amgen pay out the dividend?
The dividends of Amgen are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Amgen stock can be added to a savings plan with the following providers: Trade Republic, Scalable Capital and Consorsbank
Andere Kennzahlen von Amgen
Our stock analysis for Amgen Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Amgen Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
